CLINICAL TRIALS PROFILE FOR NORPRAMIN
✉ Email this page to a colleague
All Clinical Trials for NORPRAMIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00166114 ↗ | Depression, Epinephrine, and Platelet Function | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 4 | 2002-02-01 | Men and women who have suffered sexual and/or physical abuse before the age of 12 are at increased risk for anxiety and mood disorders, other serious psychiatric disorders, and likely medical illnesses. What is not known is whether adult survivors of childhood adversity experience heightened negative emotions and increased physical responses due to altered norepinephrine or serotonin systems in their brains and bodies. The investigators expect to see that survivors of childhood adversity experience heightened negative emotions and increased physical responses to stress. |
| NCT00166114 ↗ | Depression, Epinephrine, and Platelet Function | Completed | Emory University | Phase 4 | 2002-02-01 | Men and women who have suffered sexual and/or physical abuse before the age of 12 are at increased risk for anxiety and mood disorders, other serious psychiatric disorders, and likely medical illnesses. What is not known is whether adult survivors of childhood adversity experience heightened negative emotions and increased physical responses due to altered norepinephrine or serotonin systems in their brains and bodies. The investigators expect to see that survivors of childhood adversity experience heightened negative emotions and increased physical responses to stress. |
| NCT00338962 ↗ | Naltrexone & SSRI in Alcoholics With Depression/PTSD | Completed | Yale University | Phase 3 | 2001-10-01 | The purpose of this study is to evaluate the efficacy of naltrexone in combination with an SSRI to reduce alcohol consumption in alcoholic patients with comorbid PTSD and depression. We hypothesize that the combination of naltrexone and SSRI will exhibit a greater decrease in alcohol consumption than that seen with treatment with SSRI alone, or with a combination of another class of antidepressant and naltrexone. We also hypothesize that SSRI will be effective in treating PTSD and depressive symptoms and naltrexone will be well tolerated. |
| NCT00456014 ↗ | Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment | Completed | National Institute of Mental Health (NIMH) | N/A | 2006-09-01 | This study will use pre-treatment positron emission topography and functional magnetic resonance imaging scans of the brain to predict the most effective antidepressant treatment for people with major depressive disorder. |
| NCT00456014 ↗ | Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment | Completed | New York State Psychiatric Institute | N/A | 2006-09-01 | This study will use pre-treatment positron emission topography and functional magnetic resonance imaging scans of the brain to predict the most effective antidepressant treatment for people with major depressive disorder. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NORPRAMIN
Condition Name
Clinical Trial Locations for NORPRAMIN
Trials by Country
Clinical Trial Progress for NORPRAMIN
Clinical Trial Phase
Clinical Trial Sponsors for NORPRAMIN
Sponsor Name
